Limitless Venture Group Inc. (OTCPINK: LVGI) saw its share volume soar on May 29th with 157,874,800 shares exchanging hands, significantly higher than its three month daily average volume of 113,985,108 shares.
Limitless Venture Group recently announced that it has set up an open and public question and answer (Q&A) forum on its main website, http://www.lvginc.com.
"In the spirit of full disclosure, transparency and unprecedented access to corporate management we have decided to start our own open and public forum. This venue will level the playing field for all our loyal shareholder base and friends to openly ask questions and discuss all of LVGIs product lines with the CEO," stated LVGI CEO Joseph Francella. "Instead of people having to depend on the misinformation and possibly false information on the many message and information boards or getting that information 3rd, 4th and 5th hand, which we know always distorts that information, we are giving everyone direct access to the company and its CEO," Joe went on to say.
LVGI closed the day at $.0025 on May 29th, 78.57% higher than its previous close of $.0014.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
http://www.pennypickalerts.com
ImageWare Systems Reports First Quarter Revenues
ImageWare Systems, Inc. (OTCQB: IWSY) saw its share volume rise on May 29th with 339,637 shares exchanging hands, much higher than its three month daily average volume of 195,013 shares.
This uptick in volume comes after the company recently released its first quarter financial results for 2014.
Total revenues in the first quarter of 2014 increased to $1.1 million from $0.9 million in the first quarter of 2013, primarily due to higher sales of identification software license revenue.
Gross margin in the first quarter of 2014 increased by 410 basis points to 76.4% compared to 72.3% in the first quarter of 2013. The increase was primarily due to the increased software license revenues.
Net loss in the first quarter of 2014 was $1.7 million or ($0.02) per basic share, compared to a net loss of $2.8 million or ($0.04) per basic share in the first quarter of 2013.
At March 31, 2014, cash and cash equivalents totaled $2.2 million compared to $2.4 million at December 31, 2013. The company continues to carry virtually no debt and its $3.5 million line of credit that remains untapped.
IWSY closed the day at $2.20 on May 29th.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
http://www.pennypickalerts.com
Theralase Technologies Has Great Results From Clinical Trials
Theralase Technologies Inc. (OTCQB: TLTFF) saw its share volume skyrocket on May 29th with 1,054,918 shares exchanging hands, over ten times higher than its three month daily average volume of 99,289 shares.
This surge in volume comes after Theralase Technologies announced that in preclinical animal testing, performed at Princess Margaret Cancer Centre, University Health Network ("UHN"), it has discovered that its lead Photo Dynamic Compound (PDC), intended for the destruction of cancer, has demonstrated an ability to render animals immune to repeated exposures of the same cancer.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated, "This is one of the first preclinical trials to show that it's possible to generate a long-term anticancer memory response. For the first time in our research program, we have demonstrated that NIR PDT leads not only to long standing clearance of colon cancer cells, but also provides long lasting protection against further tumour cell challenge in young (eight to ten weeks old) and older (ten to eleven month old) mice. It is our first step toward the long-term goal of developing an affordable and practical vaccine to prevent cancer recurrence. The next steps are to further validate this research with additional animals and then find the best way of translating this research into a human clinical trial. To complete our preclinical and clinical development in this ground breaking work, we are collaborating with experts in medical biophysics, immunology and clinical oncology at UHN and with other internationally acclaimed clinical research institutes to further advance this remarkable platform technology."
TLTFF closed the day at $.364 on May 29th, 57.58% higher than its previous close of $.231.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
http://www.pennypickalerts.com
ABOUT US:
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Disclosure:
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.